Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

BioXcel Therapeutics (BTAI) EBITDA Margin (2022 - 2025)

Historic EBITDA Margin for BioXcel Therapeutics (BTAI) over the last 4 years, with Q3 2025 value amounting to 14518.37%.

  • BioXcel Therapeutics' EBITDA Margin fell 73721100.0% to 14518.37% in Q3 2025 from the same period last year, while for Sep 2025 it was 6738.3%, marking a year-over-year decrease of 33715600.0%. This contributed to the annual value of 2967.56% for FY2024, which is 94804100.0% up from last year.
  • Latest data reveals that BioXcel Therapeutics reported EBITDA Margin of 14518.37% as of Q3 2025, which was down 73721100.0% from 13210.0% recorded in Q2 2025.
  • Over the past 5 years, BioXcel Therapeutics' EBITDA Margin peaked at 449714.29% during Q1 2022, and registered a low of 28459.85% during Q3 2022.
  • Its 4-year average for EBITDA Margin is 19738.34%, with a median of 7146.26% in 2024.
  • Per our database at Business Quant, BioXcel Therapeutics' EBITDA Margin crashed by 2000000000bps in 2023 and then soared by 207016800bps in 2024.
  • BioXcel Therapeutics' EBITDA Margin (Quarter) stood at 22224.37% in 2022, then soared by 76bps to 5285.9% in 2023, then skyrocketed by 46bps to 2866.94% in 2024, then tumbled by -406bps to 14518.37% in 2025.
  • Its EBITDA Margin was 14518.37% in Q3 2025, compared to 13210.0% in Q2 2025 and 6011.31% in Q1 2025.